VNET Group Inc vs Zimmer Biomet Holdings Inc — how do they compare? VNET Group Inc trades at $6.57 (market cap $1.92B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 9.4× VNET Group Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.02% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| VNET | ZBH | |
|---|---|---|
Market Cap | $1.92B | $17.97B |
Sector | Technology | Health |
52-Week High | $14.03 | $104.26 |
52-Week Low | $6.06 | $79.58 |
Enterprise Value | $5.48B | $25.04B |
Dividend Yield | — | 1.02% |
Signals from Pluang's Aura AI — not financial advice
VNET Group trades at $6.75, up 5.97% today, amid bearish technical signals and mixed fundamentals. The company reported Q2 2026 revenue growth driven by wholesale data center demand but missed earnings expectations with a net loss. Despite a strategic partnership with CATL announced August 2026, negative profit margins and rising leverage remain concerns. Analyst consensus is bullish with 62.5% buy ratings, though technical indicators show selling pressure.
Outlook: Growth potential exists from AI infrastructure demand and new capacity, but high debt and consistent losses pose significant risks. Investors should weigh strong institutional support against fundamental weaknesses and ongoing class action litigation.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Trailing returns across standard periods
Latest headlines on both assets
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →